Conference Proceedings

Evaluating the influence of baseline disease characteristics on efficacy of a selective oral TYK2 inhibitor, BMS-986165, in patients with moderate-to-severe plaque psoriasis in a phase 2 trial

Kenneth Gordon, Kim Papp, Melinda Gooderham, Diamant Thaci, Peter Foley, Subhashis Banerjee, Sudeep Kundu, Renata Kisa, Andrew Napoli, Akimichi Morita

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | MOSBY-ELSEVIER | Published : 2019

Grants

Funding Acknowledgements

Supported by Bristol-Myers Squibb.